Page 83 - CPG - Clinical Practice Guidelines - Management of Cancer Pain

Management of Cancer Pain (Second Edition)

+DGOH\ * 'HUU\ 6 0RRUH 5$ HW DO 7UDQVGHUPDO IHQWDQ\O IRU FDQFHU SDLQ
&RFKUDQH 'DWDEDVH 6\VW 5HY &'
1RPXUD 0 .DPDWD 0 .RMLPD + HW DO 6L[ YHUVXV K FRQYHUVLRQ PHWKRG IURP
intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
6XSSRUW &DUH &DQFHU
.LQJ 6 )RUEHV . +DQNV *: HW DO $ V\VWHPDWLF UHYLHZ RI WKH XVH RI RSLRLG
medication for those with moderate to severe cancer pain and renal impairment:
a European Palliative Care Research Collaborative opioid guidelines project.
Palliat Med. 2011;25(5):525-552.
40. Paice JA, Bohlke K, Barton D, et al. Use of Opioids for Adults With Pain From
&DQFHU RU &DQFHU 7UHDWPHQW $6&2 *XLGHOLQH - &OLQ 2QFRO
:DWVRQ 0 :DUG 6 9DOODWK 1 HW DO 2[IRUG +DQGERRN RI 3DOOLDWLYH &DUH 2[IRUG
2[IRUG 8QLYHUVLW\ 3UHVV
42. Hall LM, O'Lenic K. Treatment strategies to overcome end-of-dose failure with
oral and transdermal opioids. J Pharm Pract. 2012;25(5):503-509.
$]KDU $ .LP <- +DLGHU $ HW DO 5HVSRQVH WR 2UDO ,PPHGLDWH 5HOHDVH 2SLRLGV
for Breakthrough Pain in Patients with Advanced Cancer with Adequately
Controlled Background Pain. Oncologist. 2019;24(1):125-131.
&XUURZ '& &ODUN . /RXZ 6 HW DO $ UDQGRPL]HG GRXEOH EOLQG FURVVRYHU GRVH
ranging study to determine the optimal dose of oral opioid to treat breakthrough
pain for patients with advanced cancer already established on regular opioids.
Eur J Pain. 2020;24(5):983-991.
=HFFD ( %UXQHOOL & &HQWXULRQL ) HW DO )HQWDQ\O 6XEOLQJXDO 7DEOHWV 9HUVXV
6XEFXWDQHRXV 0RUSKLQH IRU WKH 0DQDJHPHQW RI 6HYHUH &DQFHU 3DLQ (SLVRGHV
in Patients Receiving Opioid Treatment: A Double-Blind, Randomized,
Noninferiority Trial. J Clin Oncol. 2017;35(7):759-765.
9HOi]TXH] 5LYHUD , 0XxR] *DUULGR -& *DUFtD 9HODVFR 3 HW DO (I¿FDF\ RI
sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Adv
Ther. 2014;31(1):107-117.
0HUFDGDQWH 6 %UXHUD ( 2SLRLG VZLWFKLQJ LQ FDQFHU SDLQ )URP WKH EHJLQQLQJ WR
nowadays. Crit Rev Oncol Hematol. 2016;99:241-248.
6FKXVWHU 0 %D\HU 2 +HLG ) HW DO 2SLRLG 5RWDWLRQ LQ &DQFHU 3DLQ 7UHDWPHQW
Dtsch Arztebl Int. 2018;115(9):135-142.
1LFKROVRQ $% :DWVRQ *5 'HUU\ 6 HW DO 0HWKDGRQH IRU FDQFHU SDLQ &RFKUDQH
'DWDEDVH 6\VW 5HY &'
0HUFDGDQWH 6 %UXHUD ( 0HWKDGRQH DV D )LUVW /LQH 2SLRLG LQ &DQFHU 3DLQ
0DQDJHPHQW $ 6\VWHPDWLF 5HYLHZ - 3DLQ 6\PSWRP 0DQDJH
1003.
6DQGH 7$ /DLUG %- )DOORQ 07 7KH XVH RI RSLRLGV LQ FDQFHU SDWLHQWV ZLWK UHQDO
LPSDLUPHQW D V\VWHPDWLF UHYLHZ 6XSSRUW &DUH &DQFHU
52. Hughes LT, Raftery D, Coulter P, et al. Use of opioids in patients with cancer
ZLWK KHSDWLF LPSDLUPHQW D V\VWHPDWLF UHYLHZ %0- 6XSSRUW 3DOOLDW &DUH
2022;12(2):152-157.
:LIIHQ 3- 'HUU\ 6 0RRUH 5$ ,PSDFW RI PRUSKLQH IHQWDQ\O R[\FRGRQH RU
codeine on patient consciousness, appetite and thirst when used to treat cancer
SDLQ &RFKUDQH 'DWDEDVH 6\VW 5HY &'
2RVWHQ $: 2OGHQPHQJHU :+ 0DWKLMVVHQ 5+ HW DO $ 6\VWHPDWLF 5HYLHZ RI
3URVSHFWLYH 6WXGLHV 5HSRUWLQJ $GYHUVH (YHQWV RI &RPPRQO\ 8VHG 2SLRLGV IRU
&DQFHU 5HODWHG 3DLQ $ &DOO IRU WKH 8VH RI 6WDQGDUGL]HG 2XWFRPH 0HDVXUHV -
Pain. 2015;16(10):935-946.
$ERX .DVVHP ' .XULWD *3 6M¡JUHQ 3 HW DO /RQJ WHUP RSLRLG WUHDWPHQW DQG
endocrine measures in patients with cancer-related pain: a systematic review.
6FDQG - 3DLQ

65

e-cpg inside text-Cancer pain-25/5/24.indd 65 09/08/2024 12:09 AM